Korean biotech developing an RNAi (siRNA) therapeutics platform, licensing candidates for eye, skin and other diseases to global partners.
Korean biotech developing an RNAi (siRNA) therapeutics platform, licensing candidates for eye, skin and other diseases to global partners.
No product sales; income is licence payments, such as an upfront fee when a partner signs and milestones if its programmes progress, so revenue is irregular and depends on partners. It develops drugs through early stages and typically relies on partners for the later, costlier ones.
Moat: narrow (IP / patents). Proprietary asymmetric siRNA (cp-asiRNA) platform, a differentiated RNAi drug-design approach.
Headquarters: Suwon, South Korea · Founded: 2010 · Employees: 76
Size OliX Pharmaceuticals (226950.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.35B, the 191st largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩78,500 on 18 Nov 2026.
Performance Over six months the shares fell 51.1%, against -14.6% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue grew 26.6% over the last twelve months (peer median +10.1%); the operating margin is -384.5% (peer median 11.3%).
Valuation It trades at 125.0× enterprise value to sales against a peer median of 3.8× (4th most expensive of 18).
Capital Return on invested capital runs 79.0 points below its cost of capital (6.1% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩12.9B | ₩14.7B | ₩5.68B | ₩17.1B | ₩9.32B |
| Revenue growth | — | +158% | -67% | +83% | — |
| Gross profit | ₩10.6B | ₩12.2B | ₩3.05B | ₩14.4B | ₩7.35B |
| EBITDA | -₩47.2B | -₩27.5B | -₩28.3B | -₩15.5B | -₩20.4B |
| Net income | -₩17.5B | -₩15.7B | -₩40.7B | -₩19.1B | -₩19.5B |
| Free cash flow | -₩48.7B | -₩17.2B | -₩42.1B | -₩29.9B | -₩32.9B |
| Capital expenditure | ₩1.92B | ₩1.86B | ₩14.1B | ₩8.96B | ₩2.53B |
| Total debt | ₩20.7B | ₩23.3B | ₩39.2B | ₩39.4B | ₩44.0B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| OliX Pharmaceuticals 226950.KS | $1.35B | -51% | +27% | -384% | 125.0× | n/a |
| Alnylam Pharmaceuticals ALNY | $20.0B | -50% | +56% | 20% | 3.9× | 0.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 226950.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.6% | -1.8% | 2nd lowest of 20 |
| 6-month return | -51.1% | -14.6% | 2nd lowest of 20 |
| Distance from 52-week high | -63.8% | -40.0% | 4th lowest of 20 |
| Revenue growth (TTM) | +26.6% | +10.1% | 3rd highest of 18 |
| Operating margin | -384.5% | 11.3% | 4th lowest of 18 |
| EV / Sales | 125.0× | 3.8× | 4th most expensive of 18 |
| ROIC minus cost of capital | -79.0 pp | -0.5 pp | 4th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| OliX Pharmaceuticals 226950.KS | South Korea | $1.35B | -51% | +27% | -384% | 125.0× | n/a | n/a |
| Nanobiotix NANO.PA | France | $1.35B | -32% | -77% | -392% | 146.3× | n/a | n/a |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 3.0× | 3.9% | +22.8% |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | 4.7× | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | 3.0× | 10.2% | +18.1% |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.39B | -19% | +1% | 19% | 2.1× | -9.6% | +4.6% |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 9.6× | 25.9% | +23.1% |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 4.0× | n/a | n/a |
| Innoviva INVA | United States | $1.31B | -17% | +12% | 38% | 2.2× | -17.2% | +3.9% |
| Ocular Therapeutix OCUL | United States | $1.31B | -26% | -10% | -681% | 17.0× | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 12.8× | n/a | n/a |
| Damora Therapeutics DMRA | United States | $1.42B | -5% | n/a | n/a | n/a | n/a | n/a |
| Nippon Shinyaku 4516.T | Japan | $1.42B | -20% | +18% | 18% | 0.8× | -18.1% | +7.0% |
| Marksans Pharma MARKSANS.NS | India | $1.43B | +36% | +24% | 20% | 3.8× | 31.0% | +16.6% |
| Voronoi 310210.KS | South Korea | $1.43B | -62% | -100% | -438,152% | 85,633.6× | n/a | n/a |
| Mezzion Pharma 140410.KS | South Korea | $1.43B | -15% | +13% | -211% | 216.0× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 2.0× | -0.4% | -1.3% |
| Phibro Animal Health PAHC | United States | $1.44B | +5% | +10% | 13% | 1.4× | -6.4% | +12.7% |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 2.3× | 2.5% | +15.5% |